TNDM Stock Down -34% after 5-Day Loss Streak
Tandem Diabetes Care (TNDM) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -34% return. The company has lost about $233 Mil in value over the last 5 days, with its current market capitalization at about $678 Mil. The stock remains 71.9% below its value at the end of 2024. This compares with year-to-date returns of 8.4% for the S&P 500.
TNDM designs and commercializes insulin delivery systems, data management apps, continuous glucose monitoring, and blood glucose meters for people with insulin-dependent diabetes globally. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell TNDM.
Comparing TNDM Stock Returns With The S&P 500
The following table summarizes the return for TNDM stock vs. the S&P 500 index over different periods, including the current streak:
- Intuit Stock: Strong Cash Flow Poised for a Re-Rating?
- Five-Year Tally: Lowe’s Companies Stock Delivers $50 Bil Gain
- Five-Year Tally: Mastercard Stock Delivers $60 Bil Gain
- Palantir Technologies Stock Hits Key Support – Buying Opportunity?
- Stronger Bet Than Ross Stores Stock: BURL, URBN Deliver More
- Why APP, FICO Could Outperform Cadence Design Systems Stock
| Return Period | TNDM | S&P 500 |
|---|---|---|
| 1D | -9.9% | -0.3% |
| 5D (Current Streak) | -34.4% | 0.7% |
| 1M (21D) | -35.1% | 1.8% |
| 3M (63D) | -56.0% | 12.6% |
| YTD 2025 | -71.9% | 8.4% |
| 2024 | 21.8% | 23.3% |
| 2023 | -34.2% | 24.2% |
| 2022 | -70.1% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: TNDM Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 49 S&P constituents with 3 days or more of consecutive gains and 62 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 27 | 37 |
| 4D | 11 | 14 |
| 5D | 1 | 9 |
| 6D | 8 | 0 |
| 7D or more | 2 | 2 |
| Total >=3 D | 49 | 62 |
Key Financials for Tandem Diabetes Care (TNDM)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $747.7 Mil | $940.2 Mil |
| Operating Income | $-233.2 Mil | $-99.1 Mil |
| Net Income | $-222.6 Mil | $-96.0 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $234.4 Mil | $240.7 Mil |
| Operating Income | $-120.9 Mil | $-31.9 Mil |
| Net Income | $-130.6 Mil | $-52.4 Mil |
The losing streak TNDM stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.